Page 18 - குழு க்கு மருத்துவ ப்ராடக்ட்ஸ் மனிதன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) SHELTON, CT / ACCESSWIRE / March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the Company ), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the strong effectiveness of its two COVID-19 clinical drug candidates in an animal model of coronavirus infection. The Company is preparing a pre-IND application encompassing its two clinical drug candidates for the treatment of COVID-19 infected patients. Of these, NV-CoV-2 is the Company s broad-spectrum anti-coronavirus drug candidate based on its nanoviricides® platform that is expected to be capable of attacking most, if not all, SARS-CoV-2 variants and other coronaviruses. In addition, the Company is also developing NV-CoV-2-R that combines (1) the power of NV-CoV-2 to attack and potentially dismantle the virus particles outside cells, and (2) the power of remdesivir to block further production of virus particles inside cells. Blocking the com

United statesDan verganoAnthony fauciRemdesivir vekluryExchange commissionCommittee for medicinal products humanNanoviricides incTheracour pharma incEuropean medicines agencyDrug administrationSecurities exchangeBuzzfeed newsBetter surrogate virusMol medHuman immunodeficiency virusHepatitisb virus